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A B S T R A C T
Doxofylline is an eﬀective bronchodilator for relieving airway obstruction in patients with asthma or chronic
obstructive pulmonary disease (COPD), and displays a better safety proﬁle with respect to theophylline. Herein,
we performed a pairwise meta-analysis of the currently available data to provide consistent and homogeneous
ﬁndings on the impact of this xanthine in COPD patients. Results obtained from 820 patients were selected from
20 clinical trials. Meta-regression was performed to examine the source of heterogeneity between-studies and
identify potential confounder covariates. The quality of the evidence was assessed by the GRADE system.
Doxofylline induced a signiﬁcant (P < 0.001) increase in forced expiratory volume in 1 s (FEV1) of 8.20%
(95%CI 4.00–12.41; I2 93%) and 317ml (95%CI 19–439; I2 87%) compared with baseline. The total adminis-
tered dose of doxofylline signiﬁcantly (P < 0.001) interacted with the size of the eﬀect estimates detected for
FEV1. Doxofylline induced a signiﬁcant (P < 0.001), although moderate, increase in adverse events (AEs)
frequency (proportion 0.03, 95%CI 0.02–0.04; I2 88%), but only epigastralgia, nausea, dyspepsia and headache
were statistically signiﬁcant (P < 0.05). The GRADE analysis indicated high quality of evidence (++++) for
the impact of doxofylline on FEV1, and moderate quality of evidence (+++) for the safety proﬁle in COPD
patients. Doxofylline is an eﬀective and safe medicine when administered to patients with COPD and can be
considered as an alternative to theophylline.
1. Introduction
Doxofylline is a xanthine that is structurally diﬀerent from theo-
phylline by having a dioxalane group at position 7 of the xanthine ring
[1]. Consequently, it has mechanisms of action distinct from those of
theophylline [2–4] in that lacks adenosine receptor antagonism or the
ability to inhibit any of the known PDE isoforms, which may contribute
to the better safety proﬁle. Furthermore, unlike theophylline, doxofyl-
line does not interact with histone deacetylases [3], but is able to po-
sitively interact with β2-adrenoceptors [5].
The narrative analysis of literature has suggested that doxofylline is
an eﬀective bronchodilator for relieving airway obstruction in patients
with asthma or chronic obstructive pulmonary disease (COPD) and
displays a better safety proﬁle with respect to theophylline, having a
favourable risk-to-beneﬁt ratio [2,4,6]. Unfortunately, narrative re-
views primarily focused on the conclusions reached in various studies
[7] and, furthermore, mainly related with the researchers' personal
preference. Therefore, in evaluating this type of research, one needs to
examine how the critical analysis was done, ensuring the rigor in the
methodology and the review process, and checking for possible bias
stemming from the researchers' choices surrounding the development of
the research aim/question, the selection of articles to review, and the
transparency in their process or lack of it [8].
Meta-analysis, which is an analytical technique designed to sum-
marize the results of multiple studies, represents a powerful way to
eﬀectively increase sample size to provide a more valid pooled estimate
[9]. Meta-analysis can be considered as a systematic study of all studies
that have been conducted to answer a speciﬁc question or hypothesis
[10]. Actually, the meta-analytic approach usually has four main goals:
(1) to evaluate the consistency/variability of the results between the
primary studies included in the review (i.e., the between-study het-
erogeneity); (2) to investigate and explain (if feasible) the causes of any
observed heterogeneity (e.g., through subgroup or meta-regression
analyses) to improve scientiﬁc understanding; (3) to calculate a
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summary eﬀect size along with a conﬁdence interval; and (4) to assess
the robustness of the cumulative eﬀect size through sensitivity analyses
and formal evaluations of the potential sources of study bias, including
publication bias, that stem from the primary studies and might have an
impact on the calculated summary eﬀect [8].
We have therefore investigated the use of doxofylline in the treat-
ment of patients with COPD patients using a pairwise meta-analysis of
the currently available data in order to provide consistent and homo-
geneous ﬁndings.
2. Materials and methods
2.1. Search strategy
This pairwise meta-analysis has been registered in PROSPERO (re-
gistration number: CRD42017077901; available at https://www.crd.
york.ac.uk/prospero/display_record.php?RecordID=77901), and per-
formed in agreement with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) Statement (Figure S1) [11]. This
quantitative synthesis satisﬁed all the recommended items reported by
the PRISMA-P 2015 checklist [12].
We undertook a comprehensive literature search for published and
unpublished clinical trials (both randomized and non-randomized)
evaluating the inﬂuence of doxofylline in COPD patients. Observational
studies were not included in this meta-analysis. The terms “doxofylline”
and their synonyms (doxophylline, doxoﬁlline, doxoﬁllina) were sear-
ched for the drug, and the terms “chronic obstructive pulmonary dis-
ease” OR “COPD” were searched for the disease. The search was per-
formed in the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, Scopus, Google Scholar, Web of
Science and ClinicalTrials.gov databases through September 2017, in
order to provide for relevant studies available up to September 20,
2017. Studies reporting the impact of doxophylline vs. control (placebo,
untreated subjects, baseline values) on lung function and safety in
COPD patients were included in this meta-analysis.
Two reviewers independently checked the relevant studies identi-
ﬁed from literature searches and databases. The studies were selected in
agreement with the previously mentioned criteria, and any diﬀerence in
opinion about eligibility was resolved by consensus.
2.2. Quality score, risk of bias and evidence proﬁle
The Jadad score, with a scale of 1–5 (score of 5 being the best
quality), was used to assess the quality of the studies concerning the
likelihood of biases related to randomization, double blinding, with-
drawals and dropouts [13]. A Jadad score ≥3 was deﬁned to identify
high-quality studies. Two reviewers independently assessed the quality
of individual studies, and any diﬀerence in opinion about the quality
score was resolved by consensus.
The risk of publication bias was assessed by applying the funnel plot
and Egger's test through the following regression equation: SND = a +
b × precision, where SND represents the standard normal deviation
(treatment eﬀect divided by its standard error [SE]), and precision re-
presents the reciprocal of the standard error. Evidence of asymmetry
from Egger's test was considered to be signiﬁcant at P < 0.1, and the
graphical representation of 90% conﬁdence bands are presented [13].
Meta-regression analysis was performed to examine the source of
heterogeneity between-studies and identify potential confounder cov-
ariates speciﬁcally for the primary endpoints [14].
The quality of the evidence obtained for the primary endpoints was
assessed in agreement with the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) system [15].
2.3. Data extraction
Data from included studies were extracted and checked for study
characteristics and duration, doses of doxofylline, concomitant medi-
cations, disease characteristics, ethnicity, age, gender, lung function,
safety, and Jadad score.
2.4. End points
The primary endpoints of this meta-analysis were the impact of
doxofylline vs. control in terms of changes in forced expiratory volume
in 1 s (FEV1) and frequency of adverse events (AEs). The reported
length of follow-up could not be the same across clinical trials.
Considering that the probability of detecting an AE is proportional to
the duration of treatment, in this meta-analysis data on AEs have been
normalized as a function of events per person-time (namely person-
week), in which the numerator represents the count of total AEs and the
denominator represents the given time duration multiplied by the
number of patients [16,17].
The secondary endpoints were the therapeutic eﬃcacy (the rate of
patients that achieved the 3rd or 4th rank in a four-point non-validated
scale, or that achieved the 2nd or 3rd rank in a three-point non-validated
scale, where the higher values represented greater therapeutic eﬃcacy
[18–22]), the daily use or rescue medication (short-acting β2-agonists),
and the assessment of dyspnea via Medical Research Council (MRC)
scale [23], or a non-validated dyspnea score that assessed dyspnea with
a 4-point scale [24,25]. More details concerning the scales used to as-
sess the therapeutic eﬃcacy and dyspnea are reported in the supple-
mentary data ﬁle (Table S1).
2.5. Data analysis
Results are expressed as Standardized Mean Diﬀerence (SMD), Mean
Diﬀerence (MD), Proportion (Pr), Logarithmic transformed Proportion
(Log Proportion, PLN), and 95% conﬁdence interval (95%CI). The
overall changes in FEV1 are reported as SMD (SMD = [diﬀerence in
mean outcome between groups]*[standard deviation of outcome
among participants]−1), since this outcome was not always described in
a standard manner across the studies (sometimes expressed as % pre-
dicted instead of volume [L or ml]). SMD has been also re-expressed in
agreement with the rules of thumb proposed by Cohen and The
Cochrane Collaboration® [17,26]. Speciﬁcally< 0.5 represents a small
eﬀect, 0.5 to 0.8 a moderate eﬀect, 0.8 to 1.3 a large eﬀect, and>1.3 a
very large eﬀect. The subset analyses of the changes in FEV1 speciﬁcally
expressed as % or volume (L or ml) are reported as MD. The frequency
of AEs and the therapeutic eﬃcacy are reported as Pr since most studies
(85%) compared doxofylline vs. active comparators and not vs. pla-
cebo. Data on symptoms (dyspnea scores) are reported as MD and the
use of rescue medication as PLN.
Since data were selected from a series of studies performed by re-
searchers operating independently, and a common eﬀect size cannot be
assumed, we used the random-eﬀects model in order to balance the
study weights and to adequately estimate the 95%CI of the mean dis-
tribution of drugs eﬀect on the investigated variables [27].
Subset analyses were performed with regard to the quality of studies
(Jadad score ≥3), the units by which FEV1 was reported in the studies
(% predicted, volume [L or ml]), and speciﬁc AEs.
A pooled analysis was performed to calculate the frequency of AEs,
ranked in agreement with the “European Medicine Agency, section 4.8:
Undesirable eﬀects”, as follows: very common ≥1/10, common ≥1/
100 to< 1/10, uncommon≥1/1000 to< 1/100, frequency not known
if not calculable from the available data (http://www.ema.europa.eu/
docs/en_GB/document_library/Presentation/2013/01/WC500137021.
pdf).
OpenMetaAnalyst [28] software was used for performing the meta-
analysis and meta-regression, GraphPad Prism (CA, US) software to
graph the data, and GRADEpro to assess the quality of evidence [15].
The statistical signiﬁcance was assessed for P < 0.05, and moderate to
high levels of heterogeneity were considered for I2> 50%.
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3. Results
3.1. Studies characteristics
Results obtained from 820 COPD patients were selected from 20
studies [18–25,29–40] published between 1988 and 2016. The relevant
studies and patients characteristics are described in Table S2. All stu-
dies were full-text papers but two that were congress abstracts [35,37].
Five studies had a Jadad score ≥3 [18,19,23,34,40], thirteen studies
had a Jadad score ≥1 and < 3 [20–22,24,25,29–33,36,38,39],
whereas for two studies it was not possible to calculate Jadad score
[35,37]. The period of treatment ranged from one day to 52 weeks.
3.2. Quantitative synthesis
3.2.1. Primary endpoints
Doxofylline elicited a beneﬁcial impact on the primary endpoints of
this meta-analysis. The treatment with doxofylline signiﬁcantly
(P < 0.001) increased FEV1 compared to control (SMD 1.14, 95%CI
0.79–1.49; I2 88%). Speciﬁcally, doxofylline induced a large to very
large improvement in FEV1, in agreement with the rules of thumb for
the interpretation of eﬀect sizes on the basis of SMDs (Fig. 1) [17,26].
The subset analysis performed by assessing exclusively randomized
clinical trials (RCTs) indicated that doxofylline induced a signiﬁcant
(P < 0.001) increase in FEV1 of 8.20% (95%CI 4.00–12.41; I2 93%)
and 324ml (95%CI 161–487; I2 91%), compared to baseline (Fig. 2A
and B). A further subset analysis carried out considering exclusively the
high-quality studies conﬁrmed the relevant impact of doxofylline on
FEV1 (MD 239ml, 95%CI 167–311; I2 0%; P < 0.001 vs. control)
(Fig. 2C).
The overall analysis of the safety proﬁle showed that the adminis-
tration of doxofylline in COPD patients induced a signiﬁcant
(P < 0.001) but moderate increase of AEs frequency (Pr 0.03, 95%CI
0.02–0.04; I2 88%) (Fig. 3).
However, the subset and pooled analysis showed that among the
speciﬁc AEs reported in the studies, only the frequencies of epigas-
tralgia, nausea, dyspepsia and headache were signiﬁcantly (P < 0.05)
increased in patients receiving doxofylline (Fig. 4, Table 1). Overall,
2.24% patients withdrew from the studies due to AEs.
3.2.2. Secondary endpoints
Doxofylline elicited also a beneﬁcial impact on secondary end-
points. A signiﬁcant proportion (P < 0.001) of patients treated with
doxofylline achieved a high level of therapeutic eﬃcacy (Pr 0.82,
95%CI 0.77–0.87; I2 30%), and the daily use of rescue medication
signiﬁcantly (P < 0.001) decreased more than three folds during the
treatment (PLN -1.15, 95%CI -1.76 to −0.54; I2 98%). The overall
improvement of dyspnea score induced by doxofylline was greater than
one point (MD -1.03, 95%CI -1.09 to −0.97 I2 0%; P < 0.001 com-
pared with control).
3.3. Risk of bias and evidence proﬁle
A substantial and signiﬁcant (P < 0.001) level of heterogeneity
resulted in this pairwise meta-analysis concerning the primary end-
points. The sensitivity analysis indicated that the main source of het-
erogeneity was related to the clinical trials of Cipri et al. [24], Di Ve-
nanzio et al. [31], and Oreﬁce et al. [36] when the analysis was focused
on the impact of doxofylline on FEV1, and with the studies of Cipri et al.
[24] and Wu et al. [21] when it was focused on the frequency of AEs. In
Fig. 1. Overall forest plot of the impact of doxofylline vs. control on the SMD in FEV1 in COPD patients. The eﬀect size of doxofylline with regard to the improvement
in FEV1 reported as SMD has been re-expressed in agreement with the rules of thumb proposed by Cohen and The Cochrane Collaboration® [17,26]. Speciﬁcally< 0.5
represents a small eﬀect, 0.5 to 0.8 a moderate eﬀect, 0.8 to 1.3 a large eﬀect, and> 1.3 a very large eﬀect. For each study the daily dose, route of administration,
comparator and the method for expressing FEV1 are reported. COPD: cronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s; SMD: Standardized
Mean Diﬀerence.
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fact, acceptable levels of heterogeneity were found for both the primary
endpoints when these studies were excluded from the meta-analysis
(FEV1: I2 42%, P=0.06; AEs I2 49%, P=0.11).
Most the meta-analyzed clinical trials enrolled stable COPD pa-
tients, but one study enrolled speciﬁcally exacerbated COPD patients
[21]. Considering that the study of Wu et al. [21] reported data on the
safety proﬁle of doxofylline but not on lung function, we assessed
whether the clinical condition of COPD patients might represent a bias
on the frequency of AEs. The sensitivity analysis indicated that no
signiﬁcant diﬀerences (P > 0.05) were found for the eﬀects estimates
on the proportion of AEs when exacerbated COPD patients were ex-
cluded from the meta-analysis.
Fig. 2. Subset analysis of the impact of doxofylline vs. control on the MD in FEV1 reported as % predicted (A) or volume (ml, B) by including exclusively data
extracted from RCTs. Non-randomized studies and studies for which the allocation strategy was not reported have been excluded by this subset analysis. A further
subset analysis (C) shows the impact of doxofylline vs. control on lung function by considering exclusively the high-quality studies characterized by a Jadad score≥3
in which FEV1 was expressed as volume (ml). For each study the daily dose, route of administration, comparator and the method for expressing FEV1 are reported.
FEV1: forced expiratory volume in 1 s; MD: Mean Diﬀerence; RCTs: randomized clinical trials.
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No signiﬁcant heterogeneity was found either for FEV1 when high
quality studies were meta-analyzed (I2= 0, P=0.42), or for the safety
proﬁle when the eﬀect estimates of the speciﬁc AEs were considered
(I2= 16, P= 0.19). Although a certain level of dispersion was detected
by the visual analysis of funnel plot (Fig. 5A and C), the lack of bias
concerning the eﬀect estimates of either the primary endpoints was
conﬁrmed by Egger's test (Fig. 5B and D).
The ethnicity, the level of bronchial reversibility, and the date of
publication from the ﬁrst clinical trial did not represent confounder
variables that may have altered the FEV1 eﬀect estimates. A signal of
confounding factor was detected for the Jadad score (sub-group ana-
lysis: low quality studies SMD 1.35, 95%CI 0.84–1.13; high quality
studies SMD 0.72, 95%CI 0.31–1.13) and the route of administration
(sub-group analysis: intravenous SMD 1.70, 95%CI 0.67–2.74; oral
SMD 1.01, 95%CI 0.63–1.39). The total dose of doxofylline adminis-
tered to patients during the studies was a confounder variable for the
FEV1 eﬀect estimates (sub-group analysis: < 30 g SMD 0.93, 95%CI
0.62–1.24; ≥30 g SMD 2.35, 95%CI 1.51–3.19).
The ethnicity, the level of bronchial reversibility, the date of pub-
lication from the ﬁrst clinical trial and the route of administration did
not represent confounder covariates with regard to the eﬀect estimates
of AEs. On the other hand, both the Jadad score (sub-group analysis:
low quality studies Pr 0.35, 95%CI 0.01–0.06; high quality studies Pr
0.07, 95%CI 0.03–0.12) and the total dose of doxofylline (sub-group
analysis: < 30 g Pr 0.07, 95%CI 0.05–0.10; ≥30 g Pr 0.004, 95%CI
0.001–0.007) were confounder variables for the frequency of AEs.
More details on meta-regression analysis and the statistical sig-
niﬁcance of confounder variables with regard to FEV1 and AEs are re-
ported in the supplementary data ﬁle (Figure S2).
The GRADE analysis indicated high quality of evidence (++++)
for the impact of doxofylline on FEV1 expressed as volume (ml), and
moderate quality of evidence (+++) for the safety proﬁle of dox-
ofylline administered in COPD patients (Table 2). The GRADE analysis
has been carried out in high quality RCTs (Jadad score ≥3), excluded
for FEV1 expressed as % of predicted because only one high quality
study [40] reported this variable.
4. Discussion
The results of this pairwise meta-analysis conﬁrm that doxofylline is
eﬀective and safe when administered to COPD patients. Compared to
the control, doxofylline signiﬁcantly improves lung function and dys-
pnea, and reduces the daily use of rescue medication more than the
proposed minimal clinically important diﬀerence (MCID) values for
COPD outcomes [42]. Similarly to all xanthines, it induces some AEs,
but they are mild in severity. In fact, although there was a numerically
larger rate of AEs in patients treated with doxofylline than in control
groups, the percentage of patients that withdrew from the clinical trials
due to AEs was low, and the most frequently reported (≥1%) AEs in
patients receiving doxofylline were epigastralgia, nausea, dyspepsia,
headache and gastrointestinal discomfort.
It is of interest that while the overall analysis of the safety proﬁle of
doxofylline in COPD showed a high level of heterogeneity, the subset
analysis of the speciﬁc AEs associated with the treatment provided no
signiﬁcant heterogeneity of the eﬀect estimates. In any case, the quality
of evidence on the safety proﬁle was acceptable concerning both the
total number of AEs and the patients that experienced at least one AE.
The ﬁndings regarding the safety proﬁle of doxofylline contrast with
the evidence that the use of theophylline at conventional doses causes a
high frequency of adverse eﬀects [43]. It is likely that the decreased
aﬃnities towards adenosine A1 and A2 receptors of doxofylline may
account for its better safety proﬁle [3].
It must be emphasized that doxofylline elicited a large to very large
improvement in FEV1, inducing a mean improvement in FEV1 of 317ml
compared to baseline values. Keeping focused exclusively on the high-
quality studies, also in this case the average improvement in FEV1 in-
duced doxofylline was large (239ml). These values are considerably
higher than those reported for theophylline in some meta-analyses
[44,45]. Intriguingly, although the study of Mutti et al. [34] provided a
huge level of dispersion with regard to the change in FEV1 reported in
ml, probably because of the low number of enrolled patients, it did not
inﬂuence either the heterogeneity or the quality of evidence when the
analysis was performed on high quality RCTs.
The change in percentage of FEV1 (8.20% increase) is weak when
Fig. 3. Overall forest plot of the impact of doxofylline vs. control on the proportion of AEs in COPD patients. Data have been grouped in agreement with the number
of patients reporting at least one AE (upper subgroup), and the total number of AEs reported in the studies included in this meta-analysis (lower subgroup). AE:
adverse event; COPD: chronic obstructive pulmonary disease.
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Fig. 4. Subset analysis of the impact of doxofylline vs. control on the proportion of speciﬁc AEs reported in the studies included in this meta-analysis. AEs: adverse
events.
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compared with the change reported in ml. Such a discrepancy can be
explained by considering that all the high quality RCTs expressed the
changes in FEV1 as volume and that the GRADE analysis provided a
high quality of evidence for this outcome. Conversely, the studies that
reported the impact of doxofylline on the percentage of change in FEV1
were low quality studies that provided just low quality of evidence.
This meta-analysis has certainly some limitations that need to be
highlighted. It has been impossible to evaluate the eﬀect of doxofylline
taking into account the severity of the disease and clinical condition of
COPD patients, the presence of comorbidities, and use of concomitant
medications. Furthermore, most clinical trials did not use a placebo as
comparator. There was also a wide range of drug exposure between the
studies analyzed, from hours to days or even months. In fact, the meta-
regression analysis, a tool that permits to quantify the impact of mod-
erator variables on study eﬀect size [46], has shown that the total dose
of doxofylline administered to patients during the studies has inﬂu-
enced the change in FEV1. In any case, our analysis does not allow us to
conclude that a longer-term treatment is better than a shorter-term
treatment regimen or that higher doses are necessary for increased se-
verity of the COPD. Nonetheless, the evidence generated by the meta-
regression analysis that a longer treatment time leads to less AEs seems
to be very interesting and maybe suggest that tolerance to AEs may be
possible following chronic treatment with doxofylline.
The limitations of this study mainly stem from the lack of speciﬁc
information in the papers that are being considered and, consequently,
cannot be overcome by further analysis. Thus, the overall results of this
quantitative synthesis should be interpreted with caution.
However we must point out that, when high quality RCTs were
meta-analyzed, the quality of evidence was high for the impact of
doxofylline on the change in FEV1 expressed as volume (ml), and ac-
ceptable with regard to the inﬂuence of doxofylline on the frequency of
AEs. The quality of the eﬀect estimates resulting from the analysis of
high quality RCTs was also conﬁrmed by the visual analysis of funnel
plot, a graphical method to check for the existence of publication bias,
and supported by Egger's test, which assesses whether the funnel plot is
symmetrical by measuring the intercept from regression of standard
Table 1
Pooled analysis of AEs extracted from the studies on doxofylline in COPD pa-
tients and ranked by frequency in agreement with EMA guidelines [41].
AEs (n) Frequency (%) Rank P
Epigastralgia 21 4.28 ++ ***
Dyspepsia 12 2.44 ++ *
Headache 12 2.44 ++ *
Nausea 9 1.83 ++ ***
Gastrointestinal discomfort 5 1.02 ++ NS
Anorexia 3 0.61 + NS
Insomnia 3 0.61 + NS
Palpitation 3 0.61 + NS
Arrhythmia 2 0.41 + NS
Constipation 2 0.41 + NS
Dry mouth 2 0.41 + NS
Pain chest 2 0.41 + NS
Anxiety/irritability 1 0.20 + NS
Dizziness 1 0.20 + NS
Other CNS disturbances 1 0.20 + NS
Sweating 1 0.20 + NS
Tremors 1 0.20 + NS
Vomiting 1 0.20 + NS
++: common (≥1/1,00 to< 1/10); +: uncommon (≥1/1000 to< 1/100);
*P < 0.05 and ***P < 0.05, in agreement with the proportion of speciﬁc AEs
reported in the studies included in this meta-analysis; AEs: adverse events;
COPD: chronic obstructive pulmonary disease; EMA: European Medicine
Agency; NS: not signiﬁcant.
Fig. 5. Funnel plot (left panels) and graphical representation of Egger's test (right panels) for the overall impact of doxofylline vs. control on the changes in FEV1 (A
and B) and the frequency of AEs (C and D). AEs: adverse events; FEV1: forced expiratory volume in 1 s; SE: standard error; SMD: standardized mead diﬀerence; SND:
standard normal deviate.
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normal deviates against precision [47].
5. Conclusions
Notwithstanding the above-mentioned limitations, this pairwise
meta-analysis suggests that in patients with COPD doxofylline acts as a
bronchodilator drug having a wider therapeutic window than theo-
phylline. These characteristics, along with its well-described anti-in-
ﬂammatory [48] and steroid sparing eﬀects [49] suggest that when a
xanthine is indicated [50], doxofylline should be considered as an al-
ternative to theophylline in the treatment of patients with COPD.
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